Novogen is a rapidly expanding international biotechnology company based in Australia and the USA.


Novogen has three key aims:



  1. To maintain its position as the world leader in the area of isoflavonoid drug technology;

  2. To convert the Novogen technology platform into products that will successfully treat and prevent the major degenerative diseases of humans;

  3. To establish a business model and investment opportunity that will return increasing value to shareholders.


 








Novogen’s NV-128 shown to target the akt-mTOR receptor in chemoresistant cancer cells
15 April 2008
San Diego – 15 April - Pre-clinical studies reviewed during an ...More



Marshall Edwards' triphendiol demonstrates potent activity against biliary cancers
14 April 2008
Novogen Limited’s subsidiary, Marshall Edwards Inc., (NASDAQ: ...More



Interview with Novogen's CEO Mr Christopher Naughton
2 April 2008
Listen to this interview online. <a ...More






Chairman's address to the 2007 Annual General Meeting.
Friday, 26 October 2007

It is with pleasure that I present to you, our valued shareholders, my address for the 2007 Annual General Meeting.


...More
 


About Novogen | Knowledge Base | Consumer Health | Pharmaceuticals | News | Investor Relations | Contact | Site Map
Copyright © 2008 Novogen The world leader in isoflavone research - with products including Promensil and Trinovin | Web Design by Newgency